Search alternatives:
largest decrease » largest decreases (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
largest decrease » largest decreases (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
441
DCT depletion leads to a significant decrease in HPV infection in HaCaTs.
Published 2017“…<p>(A) DCT antibody incubation shows the partial DCT knockdown in DCT siRNA treated cells. …”
-
442
Data_Sheet_1_Botulinum toxin A decreases neural activity in pain-related brain regions in individuals with chronic ocular pain and photophobia.docx
Published 2023“…</p>Results<p>At baseline, all subjects reported unpleasantness with light stimulation (average: 70.8 ± 32.0). Four to six weeks after BoNT-A injection, unpleasantness scores decreased (48.1 ± 33.6), but the change was not significant. …”
-
443
Data_Sheet_2_Botulinum toxin A decreases neural activity in pain-related brain regions in individuals with chronic ocular pain and photophobia.docx
Published 2023“…</p>Results<p>At baseline, all subjects reported unpleasantness with light stimulation (average: 70.8 ± 32.0). Four to six weeks after BoNT-A injection, unpleasantness scores decreased (48.1 ± 33.6), but the change was not significant. …”
-
444
Data_Sheet_1_Botulinum toxin A decreases neural activity in pain-related brain regions in individuals with chronic ocular pain and photophobia.docx
Published 2023“…</p>Results<p>At baseline, all subjects reported unpleasantness with light stimulation (average: 70.8 ± 32.0). Four to six weeks after BoNT-A injection, unpleasantness scores decreased (48.1 ± 33.6), but the change was not significant. …”
-
445
Data_Sheet_2_Botulinum toxin A decreases neural activity in pain-related brain regions in individuals with chronic ocular pain and photophobia.docx
Published 2023“…</p>Results<p>At baseline, all subjects reported unpleasantness with light stimulation (average: 70.8 ± 32.0). Four to six weeks after BoNT-A injection, unpleasantness scores decreased (48.1 ± 33.6), but the change was not significant. …”
-
446
-
447
-
448
-
449
-
450
DataSheet_2_Albinism in the largest extant amphibian: A metabolic, endocrine, or immune problem?.xlsx
Published 2022“…Albino individuals exhibited shifted transcription of MHC I isotypes, and the albino-specific isotype was characterized by increased charges and decreased space in the antigen- binding pocket, implying a drastic change in antigen specificity and a potential risk of autoimmune disorders.…”
-
451
-
452
-
453
HDAC inhibition by quisinostat synergizes with proteasome inhibition to decrease synovial sarcoma cell viability.
Published 2017“…<p>(A) In all synovial sarcoma cell lines, but not HEK293T controls, the addition of 0.005 μM of bortezomib results in a downshift of approximately a full log of quisinostat, decreasing the amount of drug required to achieve the same effect as the HDAC inhibitor alone. …”
-
454
-
455
-
456
Nilotinib decreases viability and proliferation of HEI-193 cells in a dose-dependent manner.
Published 2013“…<p>HEI-193 cells grown in PDGF-BB or GM were evaluated after 5 days of treatment with 0, 3, 5, 10 or 20 µM nilotinib. Shown, mean value of six technical replicates. *denotes significant value (<i>p</i><0.05), **denotes significant value (p<0.005) (A) Nilotinib decreased absorbance on MTS viability assay in both growth conditions. …”
-
457
Icaritin and lenvatinib treatment for unresectable localized progressive pancreatic cancer: a report of six cases
Published 2025“…</p> <p>We analyze six cases of pancreatic cancer, each undergoing a novel treatment regimen integrating chemotherapy, targeted therapy, immune therapy, and icaritin.…”
-
458
-
459
-
460